Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Abuse and Addiction: Pharmacological Phenomena

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Development of the MDMA-Assisted Psychotherapy Side Effects Tool (M-SET): a Delphi study.

BMJ open·2026

Same author

A repeated low-dose regimen of MDMA has transient next-day effects on locomotor activity, anxiety-like behavior, and brain serotonin levels, with no effect on anhedonia-like behavior, in both female and male rats.

Psychopharmacology·2026

Same author

Preliminary predictors of self-stigma among individuals in a telehealth-based treatment program for alcohol use disorder.

Alcohol, clinical & experimental research·2025

Same author

Identification and Treatment of Alcohol Use Disorder.

The New England journal of medicine·2025

Same author

Novel Benzofuran Derivatives Induce Monoamine Release and Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine.

The Journal of pharmacology and experimental therapeutics·2024

Same author

The Need to Rule Out Intranasal Self-administration of Buprenorphine-Naloxone Combinations Before Prescribing Buprenorphine Without Naloxone.

Journal of addiction medicine·2022

Same journal

Gabapentinoids for Neuropathic Pain Management: A Systematic Umbrella Review.

Current neuropharmacology·2026

Same journal

Spatial Transcriptomic Dissection of the Cellular and Molecular Architecture of Fear Memory and its Association with Memory Function.

Current neuropharmacology·2026

Same journal

Bridging Glial Cell Membrane Proteins and Mitochondria for Combating CNS Inflammatory and Neoplastic Diseases.

Current neuropharmacology·2026

Same journal

Exposure to Ketamine and 2-Fluorodeschloroketamine Impairs Mitochondrial Oxidative Phosphorylation in Human Cerebral Organoids: Implications for Neurodevelopmental Toxicity.

Current neuropharmacology·2026

Same journal

Regulated Cell Death and Neurological Diseases - Emerging Pathways and Therapeutic Implications.

Current neuropharmacology·2026

Same journal

Effects of Drugs for the Treatment of Multiple Sclerosis in Severe Acute Respiratory Syndrome Coronavirus 2 Infection on the Expression of Angiotensin-converting Enzyme 2 in vitro.

Current neuropharmacology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 29, 2026

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

Developing biomarkers for methamphetamine addiction.

John Mendelson¹, Matthew J Baggott, Keith Flower

¹Addiction and Pharmacology Research Laboratory, California Pacific Medical Center Research Institute, St Luke's Hospital 3555 Cesar Chavez San Francisco, CA 94110 USA.

Current Neuropharmacology

|September 3, 2011

Summary

This summary is machine-generated.

Researchers developed new methods to quantify methamphetamine (MA) addiction severity. These innovations include a continuous measure of MA intake and investigating Brain Derived Neurotrophic Factor (BDNF) as a biomarker for addiction.

Keywords:

Biomarker addiction.methamphetamine

More Related Videos

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Microdialysis of Ethanol During Operant Ethanol Self-administration and Ethanol Determination by Gas Chromatography

Microdialysis of Ethanol During Operant Ethanol Self-administration and Ethanol Determination by Gas Chromatography

Published on: September 5, 2012

Related Experiment Videos

Last Updated: May 29, 2026

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Microdialysis of Ethanol During Operant Ethanol Self-administration and Ethanol Determination by Gas Chromatography

Microdialysis of Ethanol During Operant Ethanol Self-administration and Ethanol Determination by Gas Chromatography

Published on: September 5, 2012

Area of Science:

Neuroscience
Addiction Medicine
Pharmacology

Background:

Methamphetamine (MA) addiction is a global epidemic affecting millions.
Current methods for tracking MA abuse, like urinalysis, offer limited quantitative data.
Objective measures are needed to assess addiction severity and treatment response.

Purpose of the Study:

To develop innovative, quantitative methods for assessing MA addiction severity.
To investigate potential biomarkers, such as drug intake quantity and Brain Derived Neurotrophic Factor (BDNF), for predicting treatment response and relapse risk.
To enhance clinical trials and patient care with objective outcome measures.

Main Methods:

Developed a continuous quantitative measure of bioavailable MA intake using deuterium-labeled l-MA.
Investigated the role of Brain Derived Neurotrophic Factor (BDNF) as a potential biomarker for MA addiction.
Studied the effects of controlled MA doses on BDNF levels and gene regulation.
Measured BDNF levels in human laboratory and clinical trial participants.

Main Results:

Established a novel, continuous method to quantify MA intake, moving beyond binary urinalysis.
Observed that low BDNF levels are associated with addictive disorders, while elevated levels are seen in recovering MA addicts.
Initiated investigations into MA's effects on BDNF levels and gene regulation.

Conclusions:

New objective and quantifiable outcome measures can improve the assessment of MA addiction severity.
BDNF shows promise as a biomarker for MA addiction, potentially indicating disease state or recovery.
These advancements are expected to benefit both patients and clinical researchers in managing MA addiction.